NASDAQ: FTRE · Biotechnology
Fortrea Holdings (FTRE) fair value and price range
As of 3 Oct 2026, Faircurve's model values Fortrea Holdings (FTRE) at $20.12 a share. The stock last closed at $20.00, which puts the model's fair value 0.6% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 2 Oct 2026. Fortrea Holdings Inc.
Faircurve Insights · 3 Oct 2026
Fortrea Holdings Inc. functions as a global contract research organisation (CRO), concentrating on providing development services for biopharmaceutical products and medical devices.
Faircurve's model found a fair value of $20.12 a share for Fortrea Holdings Inc. on 3 Oct 2026, the midpoint of 2,000 simulations. The model's fair value moved -11.6% since the previous run on 26 Sep 2026, which gave $22.77. The calibrated range is $16.79 to $24.39, built from the fair value and calibrated weekly against realised prices, and held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown.
The model compares Fortrea Holdings Inc. with Sarepta Therapeutics, Inc. (SRPT), Vericel Corporation (VCEL), ADMA Biologics, Inc. (ADMA), and Arcus Biosciences, Inc. (RCUS). The stock's moves around the last eight earnings reports ranged from -20.9% to +27.7%, with a median size of 15.6%.
Written from the figures on this page for the 3 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give FTRE?
The calibrated range for FTRE over 63 trading days is $16.79 to $24.39. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,809 past valuations, refreshed 3 Oct 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $11.10 to $32.24. In 50% of the simulations the fair value came out above the price the model ran on.
How does FTRE compare with similar companies?
The companies in biotechnology closest to Fortrea Holdings in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| VIR Vir Biotechnology, Inc. | $11.17 | $10.83 | -3.0% | Low evidence grade |
| SRPT Sarepta Therapeutics, Inc. | $17.50 | $23.95 | +36.9% | Undervalued |
| XNCR Xencor, Inc. | $24.84 | $23.14 | -6.8% | Data under review |
| VCEL Vericel Corporation | $40.15 | $46.49 | +15.8% | Undervalued |
| ADMA ADMA Biologics, Inc. | $9.72 | $11.35 | +16.8% | Undervalued |
| HRMY Harmony Biosciences Holdings, Inc. | $39.64 | $39.86 | +0.6% | Low evidence grade |
| INVA Innoviva, Inc. | $20.50 | $20.57 | +0.3% | Low evidence grade |
| RCUS Arcus Biosciences, Inc. | $24.44 | $22.88 | -6.4% | Fairly valued |
When does FTRE report earnings, and how has the stock reacted?
Fortrea Holdings's next earnings report is scheduled for 5 Nov 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 24.3% in either direction through the nearest expiry, about 48 days out, a window that includes the report. That is the size the market is pricing, not a direction.
How FTRE moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 15.6%.
| Report date | Two session move |
|---|---|
| 29 Jul 2026 | -7.8% |
| 5 May 2026 | +27.7% |
| 26 Feb 2026 | +3.7% |
| 5 Nov 2025 | +13.6% |
| 6 Aug 2025 | +10.4% |
| 12 May 2025 | -17.5% |
| 3 Mar 2025 | -20.9% |
| 8 Nov 2024 | +26.0% |
Fortrea Holdings at a glance
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices.
- Market value
- $1.9B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $2.7B
- Consensus revenue growth, next fiscal year
- -2.2%
- Analysts with estimates
- 7
- Beta to the US market
- 2.17
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Fortrea Holdings on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 26 Sep 2026 the model's fair value for FTRE was $22.77. As of 3 Oct 2026 it is $20.12, a change of -11.6%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Fortrea Holdings's valuation
Is Fortrea Holdings stock undervalued or overvalued?
Faircurve's model puts FTRE's fair value at $20.12 a share against a last close of $20.00, as of 3 Oct 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is FTRE's fair value?
$20.12 a share as of 3 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $11.10 to $32.24.
What price range does the model give FTRE?
$16.79 to $24.39 over 63 trading days. Ranges built this way held the price 60% of the time across 4,809 past valuations, refreshed 3 Oct 2026.
When does Fortrea Holdings report earnings next?
The next report is scheduled for 5 Nov 2026. Companies can move their dates.
How much has FTRE moved on past earnings reports?
Across its last 8 reports the median two session move was 15.6%, ignoring direction. The largest was +27.7% around the report of 5 May 2026.
How confident is the model in this valuation?
The model's evidence grade for FTRE is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.